We next performed a dual immunofluorescence analysis of ID2 and CHGA on samples from clinical neuroendocrine carcinoma and adenocarcinoma of the prostate, with the former being positive for CHGA and strongly positive for ID2, whereas in the latter, it was negative for CHGA and weakly positive for ID2 (Figure 1A and Figure S1B). The gene discussed is ID2; the disease is prostate adenocarcinoma.